Correlation Between Cytek Biosciences and Neuropace

Can any of the company-specific risk be diversified away by investing in both Cytek Biosciences and Neuropace at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cytek Biosciences and Neuropace into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cytek Biosciences and Neuropace, you can compare the effects of market volatilities on Cytek Biosciences and Neuropace and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cytek Biosciences with a short position of Neuropace. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cytek Biosciences and Neuropace.

Diversification Opportunities for Cytek Biosciences and Neuropace

-0.75

Correlation Coefficient

Cytek Biosciences  Neuropace

Pay attention - limited upside

The 3 months correlation between Cytek and Neuropace is -0.75. Overlapping area represents the amount of risk that can be diversified away by holding Cytek Biosciences and Neuropace in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Neuropace and Cytek Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cytek Biosciences are associated (or correlated) with Neuropace. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Neuropace has no effect on the direction of Cytek Biosciences i.e., Cytek Biosciences and Neuropace go up and down completely randomly.

Pair Corralation between Cytek Biosciences and Neuropace

Given the investment horizon of 90 days Cytek Biosciences is expected to generate 1.54 times more return on investment than Neuropace. However, Cytek Biosciences is 1.54 times more volatile than Neuropace. It trades about 0.19 of its potential returns per unit of risk. Neuropace is currently generating about -0.2 per unit of risk. If you would invest  257.00  in Cytek Biosciences on May 27, 2025 and sell it today you would earn a total of  154.00  from holding Cytek Biosciences or generate 59.92% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Cytek Biosciences  vs.  Neuropace

Cytek Biosciences

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Cytek Biosciences are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain forward-looking signals, Cytek Biosciences sustained solid returns over the last few months and may actually be approaching a breakup point.

Neuropace

Risk-Adjusted Performance

Weakest

Over the last 90 days Neuropace has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's fundamental indicators remain rather sound which may send shares a bit higher in September 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Pair Trading with Cytek Biosciences and Neuropace

The main advantage of trading using opposite Cytek Biosciences and Neuropace positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cytek Biosciences position performs unexpectedly, Neuropace can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neuropace will offset losses from the drop in Neuropace's long position.

The idea behind Cytek Biosciences and Neuropace pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.